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Recently, new treatment approaches have been developed to target the host component of periodontal disease. This review aims at providing updated information on host-
modulating therapies, focusing on treatment strategies for inhibiting signal transduction 
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STAT pathways are being developed to manage rheumatoid arthritis, periodontal disease 
	 	 
	 
	 %&	 	 	 
	
	 	
be inhibited at cell signaling level, interfering on transcription factors activation and 
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After overcoming these limitations, adjunctive host modulating drugs will provide new 
therapeutic strategies for periodontal treatment.
Key words: Periodontitis. Signal transduction. Janus kinases. STAT transcription factors. 
Mitogen-activated protein kinases. NF-kappa B.
1- ETIOLOGY AND PATHOGENESIS OF 
PERIODONTAL DISEASES
The hallmark of inflammatory/infectious 
conditions is the increased production of cytokines, 
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The synthesis and expression of these mediators 
occur in a transitory and strictly controlled 
way, seeking resolution of the problem and re-
establishment of the homeostasis. Regulation 
of cytokine gene expression is controlled by 
various mechanisms, including transcriptional, 
post-transcriptional, translational and post-
translational regulations. In the event of defective 
negative regulation of cytokine gene expression, 
the exaggerated and uncontrolled expression of 
cytokines and proteases can have deleterious 
consequences to the host, including cancer, 
autoimmune and chronic diseases2. Periodontal 
disease is one of these chronic pathologies, and it is 
			

)	&				
	
adults10. The pathologic mechanisms of periodontal 
disease are still not completely understood. 
Current knowledge concerning the pathogenesis of 
periodontitis suggests that it is a mixed infection 
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mediators. These mediators trigger a cascade 
of events that, in some individuals, culminate 
in the irreversible degradation of connective 
and bone tissues, and consequent periodontal 
attachment loss6,57. Periodontal diseases have 
unique characteristics that distinguish it from other 
common infectious diseases: there is no uniformity 
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that would result in disease in all individuals. 
Certain individuals seem to be more susceptible 
to periodontal disease and the variability in the 
host response seems to be a major cause of the 
disease extension and severity. Environmental 
and acquired risk factors as diabetes mellitus, 
psychological stress, smoking, and genetic factors 
[such as interleukin-1 (IL-1) gene polymorphisms] 
2012;20(2):128-38
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and, consequently, the susceptibility to periodontal 
disease1,40. The association of periodontal disease 
with increased levels of cytokines and pro-
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mechanisms for the negative regulation of these 
genes may be defective or dysfunctional; and 
this, in turn, may be one mechanism of increased 
susceptibility to periodontal disease.
Many studies have shown that the biological 
activity of a variety of cytokines may be directly 
relevant to periodontal destruction2,29. The 
interaction between cytokines and their antagonists 
will ultimately determine the severity and extent 
of tissue destruction, which may occur either as a 
direct effect of increased level of cytokines, or as 
indirect consequences of cytokine expression57. 
There is evidence of changes in the expression 
of these immune regulatory molecules found in 
diseased sites, compared to health clinic conditions. 
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with higher periodontal disease severity, the 
opposite is considered true for T helper 2 type 
cytokines, such as IL-4 and IL-108,19,21. The balance 
between the expression of T helper 1 and T helper 
2 type mediators is thought to be a relevant factor 
in the outcome of disease, possibly regulating the 
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metalloproteinases (MMPs)/tissue inhibitors of 
metalloproteinases (TIMPs) and receptor activator 
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(OPG). Imbalances between these mediators in the 
periodontal tissues are a major cause of periodontal 
destruction22-23,46.
2- TRADITIONAL THERAPY AND 
NEW THERAPEUTIC STRATEGIES ON 
PERIODONTAL DISEASES
The therapeutic approach to managing 
periodontal diseases has been traditionally targeted 
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maintenance82. More recently, modulation of the 
host component of periodontal disease has been 
studied as an alternative therapeutic approach. 
Manipulation of the immune response to suppress 
undesirable reactions is an established therapeutic 
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autoimmune diseases but also in cancer25,38. The 
purpose of host modulatory therapy is to restore 
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demonstrated that modulation of the host immune/
inflammatory response resulted in significant 
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in the treatment of chronic periodontitis71. The 
adjunctive use of host modulatory therapy can slow 
down the progression of the disease, especially in 
susceptible patients at increased risk for whom 
conventional therapeutic approaches are not 
effective. Importantly, modulation of host response 
can prevent and/or minimize the destruction 
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There are several strategies for modulation 
of host response. Studies suggest that certain 
local and systemic pharmacologic agents, that 
block specific inflammatory mediators, appear 
to attenuate disease progression90. Modulating 
biochemical agents and drugs have been postulated 
to be of therapeutic value as an adjunctive therapy 
to the management of chronic periodontitis28,42,65. 
The most studied drugs are antibiotics used 
in non-antimicrobial doses (e.g. tetracycline 
derivatives, which inhibit collagenolytic activities 
and activity of neutrophils and osteoclasts), anti-
inflammatory agents and bone-sparing drugs. 
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weak organic acids, which prevent prostanoid 
formation by blocking the cyclooxygenase pathway 
of arachidonic acid metabolism. The bone-
sparing drugs (e.g., bisphosphonates) bind to the 
hydroxyapatite crystals of bone and prevent their 
dissolution by interfering with osteoclasts activity, 
thus reducing alveolar bone loss.
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demonstrated successful protective effects against 
bone resorption18,44,54. The use of anti-cytokine 
therapies (by anti-cytokine drugs and soluble 
cytokine blockers) has been proven effective to 
block the negative effects of cytokines, slowing 
down the disease process. However, most of these 
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side effects, including hemorrhage, gastrointestinal 
problems, and renal and hepatic impairment 
that preclude their use. Another important 
consideration is the protective role of immune 
response and the potential hazards of its negative 
modulation, especially aggravation of infection 
as demonstrated by studies using animals with 
defective immune response and clinical studies in 
severely immunocompromised patients11,16-17.
A more recent approach to modulation of 
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the immune response is targeting cell signaling 
pathways important for their gene expression. 
One advantage of this approach is that expression 
of various inflammatory mediators requires 
activation of a limited number of these signaling 
pathways. Thus, modulation of one signaling 
Modulation of host cell signaling pathways as a therapeutic approach in periodontal disease
2012;20(2):128-38
J Appl Oral Sci. 130
pathway may affect expression of more than 
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cytokine network. This is important considering 
the frequently redundant and interchangeable 
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also implies that the impact of therapies targeting 
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be somewhat limited because of compensatory 
mechanisms30. As promising and attractive as 
these strategies may be, intracellular signaling 
pathways have some important characteristics 
that should be considered, including the fact that 
they may be essential to various cellular processes, 
such as proliferation, apoptosis and survival. This 
suggests that modulation of some cell signaling 
pathways may have negative effects; however 
another hallmark of cytokine cell signaling is that 
activation of these pathways by cytokines and 
their agonists is usually a very rapid and transient 
event (minutes) that results in somewhat long-
lasting consequences (modulation of cytokine gene 
expression). It is, thus, conceivable that a short-
term modulation of cell signaling pathways may 
have an impact on cytokine gene expression without 
having much negative consequences on other 
fundamental cellular processes. For this reason, 
it is important to understand the role of individual 
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destruction in periodontal disease. Because these 
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mediators, including many cytokines, chemokines, 
cell-adhesion molecules, acute-phase proteins and 
anti-apoptotic proteins, their inhibition will probably 
prove more progress than current treatment 
strategies. This review aims at providing updated 
information on host-modulating therapies, focusing 
on control mechanisms to inhibiting the most 
important signal transduction pathways related to 
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3- CELL SIGNALING PATHWAYS IN 
PERIODONTAL DISEASE
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the teeth area adjacent to gingival margin, an 
inflammatory process is initiated, triggering a 
dynamic cascade of events. The main purpose of 
these events is the combat of microbial invaders 
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the external antigenic stimuli by host leukocytes of 
the innate immune response, e.g. macrophages, 
neutrophils, dendritic cells, natural killer cells and 
others. This recognition of external “danger” then 
triggers a signal that travels through the cytoplasm 
and reaches the nucleus, and ultimately the pattern 
of gene expression is altered by transcriptional and 
post-transcriptional mechanisms. The ability of the 
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determine the sequence of the process. Within 3-4 
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robust to initiate connective destruction. If the 
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resolve the aggression and eliminate the “danger” 
signals, then an adaptive immune response is 
initiated, involving lymphocytes that will produce 
immunoglobulins, cytokines and also try to clear 
out the aggression by direct cytotoxic mechanisms. 
Regardless of the type of host response (innate 
or acquired immunity), all cellular events depend 
on the activation of multiple signal transduction 
pathways, which may be affected by various 
factors both microbial- and host-derived, including 
lipopolysaccharide (LPS), proteases, cytokines and 
other enzymes47,80. Signal transduction depends on 
receptor-ligand interactions which usually involves 
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associated with these receptors. The most common 
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kinases, which induces a conformational change 
on the tridimensional structure of the protein. 
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to transfer energy and modulate their biological 
activity, since it does not involve de novo gene 
expression (i.e., the signaling intermediates are 
usually constitutively expressed by the cells and 
“ready to go into action”, as soon as they are 
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varying number of signaling intermediates that 
are activated (phosphorylated) sequentially and 
relay the energy to one or more protein substrates. 
These substrates can exert their biological effect as 
transcriptional factors, transcriptional repressors, by 
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during periodontal disease progression results from 
the activation of intracellular signaling pathways, 
which are determined by the nature of extracellular 
stimuli. In periodontal disease the most important 
pathways include the mitogen activated protein 
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and janus tyrosine kinase-signal transducer and 
activator of transcription (JAK/STAT)3,20.
3.1- MAPK pathway
MAPKs are an evolutionarily conserved family of 
protein kinases that mediate fundamental biological 
processes and cellular responses to different 
extracellular stimuli through multiple receptors41. 
MAPKs are involved in signal transduction of 
extracellular hormones, growth factors, cytokines, 
bacterial antigens and environmental stresses and 
play a crucial role in many aspects of immune 
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63,67. The three 
main sub-families of MAPKs are extracellular-
SOUZA JAC, ROSSA C Jr, GARLET GP, NOGUEIRA AVB, CIRELLI JA
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regulated kinases (ERK-1/-2), c-Jun N-terminal 
activated kinases (JNK) and p38. ERK kinases are 
traditionally considered as being primarily activated 
by mitogens and growth factors while inducers of 
		*
	(
		
	
by JNKs and p3860, although this general concept 
does not apply to all cell types and to all external 
stimuli. However, there is evidence of cross-
activation and interaction between various levels 
of the main MAPKs pathways (ERK and p38)64,86. 
The MAPK cascade consists of a series of three-
tired protein kinases, a MAPK and two upstream 
components, MAPK kinase (MAPKK) and MAPKK 
kinase (MAPKKK). Activation of the MAPKs results 
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that mediate gene transcription (Figure 1). The 
multiple interactions between the different MAPK 
cascades serve to integrate the responses and 
activate separate sets of genes43,63. All three MAPK 
families are expressed in periodontal disease20.
During initial interaction of pathogens with 
the host’s immune system, pathogen-associated 
molecular patterns (PAMPs), such as LPS, 
peptidoglycans, lipoteichoic acid, or bacterial 
CpG-DNA can trigger cells of the innate immune 
system52. Cytokines produced in response to this 
initial activation by PAMPs can also activate signal 
transduction pathways by autocrine or paracrine 
mechanisms. These microbial products and 
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Toll receptors, IL-1 receptor (TIR) family or the 
TNF receptor family. Activation of these receptors 
triggers MAPK pathway (Figure 1), leading to 
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known to be relevant for cytokine gene expression43. 
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arthritis81.
p38 activation leads to increased expression 
of various cytokine genes by modulation of 
both transcriptional and post-transcriptional 
mechanisms. The contribution of each mechanism 
to the global change of gene expression varies with 
the cell type and nature of external stimulation, 
but among the genes that are at least partially 
modulated by post-transcriptional mechanisms 
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6, IL-2 and cyclooxygenase (COX)-233,61,91. Other 
genes are primarily regulated by transcriptional 
Figure 1- MAPK pathway: The three main sub-families of mitogen-activated protein kinases (MAPKs) are extracellular-
regulated kinases (ERK), c-Jun N-terminal activated kinases (JNK) and p38 that mediate immune cell functional responses 
to different extracellular stimuli through multiple receptors. The MAPK cascade consists of a series of three-tired protein 
kinases, a MAPK and two upstream components, MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK). Activation of the 
	
								

 	    	 			  	 
	 	 !  	"# $%!
activating transcription factor; ELK, Ets-like transcription factor associated kinase; MEK, MAPK/ERK Kinase; TAK, TGFb 
associated kinase
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and metalloproteinases7,70,72.
The evidence indicating a prominent role of 
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cytokine gene expression and signaling, make them 
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developed and preclinical and clinical data suggest 
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inhibitors interfere with phosphorylation or bind 
in the ATP binding site. Several compounds such 
as SD-282, SC-409, SB (SmithKline Beecham) 
-242235, AW-814141 and other capable of inhibit 
p38 have been studied in murine models of 
rheumatoid arthritis and/or periodontal disease and 
have prevented progression of the disease and bone 
resorption4,12,49,51,69. The promising results obtained 
in both in vitro and in preclinical studies generated 
interest of pharmaceutical companies to develop 
protein kinase inhibitors. The p38 inhibitor BIRB-
796 (Boehringer Ingelheim Pharmaceuticals Inc., 
V
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in a phase II study in rheumatoid arthritis but shown 
limited results15,92. Studies to evaluate the safety 
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of these compounds in arthritis appears limited and 
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was discontinued because in animal test revealed 
adverse neurological effects. Although no adverse 
effects were reported in human, gastrointestinal 
symptoms were described31,87.
Inhibitors of JNK and ERK have also shown 
efficacy in inhibiting the production of pro-
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32,89 (Figure 4). So far, 
no human trials have been initiated with these 
inhibitors. In murine model of rheumatoid arthritis, 
the JNK inhibitor SP600125 (Celgene Corporation, 
San Diego, California, USA), besides the reduction 
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also inhibit joint destruction in a rat adjuvant 
arthritis model32	^ 
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available but there is limited information about their 
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Recently, a potent and selective inhibitor for ERK, 
FR180204, has been proven effective against 
mouse collagen-induced arthritis. This compound 
Figure 2-&%"'*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and prevent their nuclear translocation. Signaling through TNF receptor (TNFR), IL-1 receptor (IL-1R), or toll-like receptor 
(TLR) can activate a cascade that involves the recruitment of MYD88 (myeloid differentiation primary response gene 88) 
and IRAK (interleukin-1-receptor associated kinase). Activation of IRAK results in the phosphorylation of TNF-receptor 
	  V ?$Z%VW! 	   < "["	 >	  ?$W ! <! 

!	\
	='*>		]?=W=			='*^	!<	


\
! ='*^&%"'*	 ='*^			$	&%"'*		
		
	
<			_&	
			$	=!
*"`jIIj		='*^				&%"'*
SOUZA JAC, ROSSA C Jr, GARLET GP, NOGUEIRA AVB, CIRELLI JA
2012;20(2):128-38
J Appl Oral Sci. 133
suppresses the activation of T cells, which play a 
important role in progress of the disease56.
The MAPK inhibitors are capable of reducing 
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rheumatoid arthritis and periodontal disease27,37,59,62. 
In several cases, however, the clinical studies have 
been stopped87. MAPKs play several physiological 
roles and suppression of these functions may lead 
to a number of problems. While many inhibitors 
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have prevented the development of some of these 
compounds. Therefore, most of these compounds 
have subsequently been discontinued. One of the 
underlying reasons for these unacceptable side 
effects might be the cross-reactivities against other 
kinases or other cellular signaling molecules14.
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that binds to a 10 base pairs (bp) DNA element in 
kappa immunoglobulin light-chain enhancer in B 
cells74	 %	 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has been shown to be involved in many different 
pathways and has a central role in regulating the 
expression of a wide variety of genes that control both 
innate and adaptive immune responses. Activated 
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quantities in tissues with periodontal disease such 
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inducible nitric oxide synthase (iNOS)5,81. In vitro 
studies have established that both Porphyromonas 
gingivalis and other periodontal pathogenic bacteria 
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a diversity of biologically active molecules is the 
consequence of the activation of other signaling 
pathways, including MAPKs and TLR pathways. A 
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recent study in patients with chronic periodontitis 
and healthy controls showed that activation of NF-
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in managing periodontitis3. In animal models of 
&
	

		


		*!"	
inhibitors seems to be effective53.
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p100), c-REL and REL-b24. These subunits, except 
REL-b, form homodimers and heterodimers to 
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cell surface results in the phosphorylation of signal transducers and activators of transcription (STATs), which then dimerize 
and translocate to the nucleus where they can regulate gene transcription. The compound CP-690550 inhibits JAK3 and 
prevents activation of JAK/STAT pathway
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is a heterodimer of p50 and p65. They bind to the 
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bind to functional NF-kB dimers in cytoplasm 
in absence of stimuli and prevent their nuclear 
translocation. Signaling through IL-1 receptor (IL-
1R) or toll-like receptor (TLR) can activate a cascade 
that involves the recruitment of MYD88 (myeloid 
differentiation primary response gene 88) and 
IRAK (interleukin-1-receptor associated kinase). 
Activation of IRAK results in the phosphorylation of 
TNF-receptor associated factor 6 (TRAF6), leading 
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protein then translocates to the nucleus where it 
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multiples genes, including cytokines, chemokines, 
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mediators (Figure 2). Many strategies to prevent 
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recombinant protein or by gene therapy9. The IKK 
inhibitor, BMS (Bristol-Myers Squibb)-345541, was 
evaluated in the collagen-induced arthritis model 
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and joint destruction50 (Figure 4). Inhibition of the 
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activity are being developed by pharmaceutical 
industries, and are based either on targeting the 
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Despite the potential use of this pathway in 
development of therapeutic interventions for 
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participates in normal physiological process. 
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unwanted side effects as liver failure related to 
hepatocyte apoptosis48.
3.3- JAK/STAT pathway
Many cytokines and growth factors (interferons, 
interleukins, epidermal growth factor, growth 
hormone, erythropoietin and others) exert their 
biological functions through JAK-STAT signal 
transduction pathway55,73. Classically, interferons 
and interleukins, cytokines with key roles in 
regulating the immune response, activate enzymes 
called Janus kinases (JAK1, JAK2, JAK3 and Tyk2), 
which are associated with the cytoplasmic portion 
of the transmembrane receptors34. Activated JAKs, 
phosphorylate the cytoplasmic domain of the 
receptor leading the activation of its substrates, 
especially the proteins known as STATs (STAT1-4, 
5a, 5b, and 6). Upon phosphorylation, STATs may 
Figure 4- Pharmacological compounds with potential host-modulation actions
Compound Target Effects
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osteoclastogenesis, and alveolar bone loss were reduced in rats model69
Cartilage and bone destruction in mice with collagen-induced arthritis were 
reversed51
SC-409 p38 Streptococcal cell wall-induced arthritis, joint swelling and bone destruction 
were attenuated in rats49
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"
	<			
	4
AW-814141 p38 =}<				<			
	12
BIRB-796 p38 Z	
	}	==
	
92
VX-702 p38 	
	
		}		
phase II study in rheumatoid arthritis15
VX-745 p38
Inhibits cartilage induced and adjuvant induced arthritis model31 but was 
discontinued because in animal test revealed adverse neurological effects87
SP600125 JNK
Reduction in the level of TNF-!=%&"!=|"V!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joint destruction in a rat adjuvant arthritis model32
FR180204 ERK Effective against mouse collagen-induced arthritis56
BMS-345541 NF-kB
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CP-690550 JAK3
	 =  ==   		 	 	  	  "
690550 in preventing transplant rejection and alleviating the symptoms of 
rheumatoid arthritis and psoriasis88
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form homo- or hetero-dimers; which enables them 
to enter to the nucleus where they can regulate 
gene transcription55 (Figure 3). Although individual 
STAT proteins may be activated by multiple ligands, 
certain cytokines preferentially activate particular 
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
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JAK1/JAK2 and IL-6 activates STAT3 through 
JAK1. This pathway is crucial to many responses 
like hematopoiesis, oncogenesis and immune/
inflammation regulation. However, abnormal 
activity of JAK/STAT pathway is associated with a 
wide variety of human malignancies such as cancer. 
Regulatory mechanisms controlling the duration 
of the signal include the downregulation of the 
receptor/ligand complex, degradation of signaling 
intermediates, inactivation of positive regulators 
by dephosphorylation (receptor, JAK or STAT) or 

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77.
The JAK-STAT pathway is the signaling target 
of many cytokines which are thought to have 
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(IFN-, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, and 
IL-15) and in periodontal disease (INF-, TNF-, 
IL-1 IL-4, IL-6, and IL-10)8,66,85. Furthermore 
preliminary studies in human synovial tissue 
suggest that constitutive STAT activity is observed 
in rheumatoid arthritis35,39. Other recent study have 
shown that STAT3 and STAT5 activations were noted 
on the ligature-induced model of experimental 
periodontitis20. To date, no studies with STAT 
inhibitors are available in periodontal disease and 
in rheumatoid arthritis, despite the potential role 
of these proteins in expression of important genes 
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Among the four JAKs, JAK3 and Tyk2 have 
been the focus of most interest in terms of drug 
development whereas experimental deficiency 
of JAK1 or JAK2 is lethal. Therefore, targeting 
these kinases would not be expected to be good 
targets58,68. At moment, no Tyk2 inhibitor was 
developed. Tyk2 was involved in signaling by type 
I IFNs84. Targeting Tyk2 would be a useful strategy 
for the treatment of Th1 mediated disorders such 
as arthritis75. The JAK3 antagonist CP-690550 
H)K		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
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)	
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	
rheumatoid arthritis88 (Figure 4).
It is now clear that JAK/STAT pathway have a 
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and progression. This pathway can affect the 
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modulation of this pathway on cytokine signaling 
increases the possibility that these proteins may 
prove to be excellent targets for the discovery of 
drugs that can manipulate cytokine outcomes to 
resolve disease.
4- CONCLUSIONS
Periodontal diseases are one of the most 
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clear that both the pathogenesis and the clinical 
manifestations of this disease are, at least in 
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responses. Wherefore, the importance of the 
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be recognized by the fact it represents the 
opportunity to explore new treatment approaches. 
The adjunctive use of modulation of host response 
with traditional mechanical periodontal therapy has 
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of periodontal disease.
Improved knowledge of signal transduction 
mechanisms and gene regulation involved in 
immune responses, notably in pathways involving 
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create new therapeutic targets useful in treating 
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blockade may be more effective than targeting 
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important in several other physiological processes 
and therefore their inhibition can also result in 
undesirable side effects.
The development of effective drugs targeting 
host response mechanisms may represent a new 
approach in adjunctive treatment of periodontal 
disease. Although these drugs offer great potential 
to modulate host response, a notable limitation of 
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	
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	
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effects. Drugs that inhibit destruction of the 
connective tissue in one periodontal site also 
interfere with wound healing at another, or worse, 
can predispose the patient to opportunist and/or 
acquired infections in other organ systems when 
these drugs are administered systemically. Thus, 
&			)
					
of periodontal disease may cause problems in other 
parts of body. Nevertheless, preliminary results 
indicate that the therapeutic potential of some of 
these drugs are promising for the management of 
&
	
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chronic diseases. In the future, it is possible that 
host modulating drugs will provide new adjunctive 
therapeutic strategies for periodontal treatment.
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